Sector News

Sigma-Aldrich acquires Duolink product portfolio from Olink Bioscience

October 30, 2015
Life sciences

Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology company, today announced that it has signed an agreement to acquire the Duolink® product portfolio from Olink Bioscience.

The acquisition includes intellectual property, sales, marketing and manufacturing assets.

The newly acquired product line is designed for researchers studying biological pathways and seeking improved sensitivity to uncover disease biomarkers. Since 2013, Sigma-Aldrich has distributed Duolink reagents, along with pre-validated antibody pairs for proximity ligation assays (in situ PLA®).

“We are excited about the acquisition of the Duolink product portfolio. Duolink is valuable to our customers and complements the rest of Sigma-Aldrich’s Protein Biology portfolio,” said Amanda Halford, Vice President, Academic Research at Sigma-Aldrich. “Owning the Duolink technology will provide Sigma-Aldrich with opportunities to develop new products, as well as advance our existing technologies.”

Duolink Technology, based on PLA technology, enables researchers to visualize low levels of proteins, protein modifications and individual protein interactions directly in fixed cells and tissue samples without the need for overexpression. This technology can significantly enhance the rigor and reproducibility of scientific experiments, aided by dual recognition of antibody pairs.

“Duolink has been a very important product in the history and development of Olink, and we feel that with this acquisition by Sigma-Aldrich, it will be in very good hands and continue to be a great success,” said Jon Heimer, CEO of Olink Bioscience. “We will now focus our resources on further developing our Proseek® Multiplex product line for human protein biomarker research, as well as expanding our global presence by establishing local commercial organizations in Europe and North America, and continuing to develop new innovative tools for the scientific community.”

“Duolink technology is transforming the way scientists study biological pathways. It allows interactions between proteins at the endogenous levels to now be visualized, providing researchers with reproducible data they can see,” said Halford. “The acquisition of Duolink allows Sigma-Aldrich to provide comprehensive solutions for enabling experimental reproducibility, with continued reliability in supply and quality.”

Source: Sigma-Aldrich

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend